PMID- 37665737 OWN - NLM STAT- MEDLINE DCOM- 20230906 LR - 20231205 IS - 1581-3207 (Electronic) IS - 1318-2099 (Print) IS - 1318-2099 (Linking) VI - 57 IP - 3 DP - 2023 Sep 1 TI - Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. PG - 397-404 LID - 10.2478/raon-2023-0040 [doi] AB - BACKGROUND: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option. PATIENTS AND METHODS: A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment. RESULTS: There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%). CONCLUSIONS: The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT. CI - (c) 2023 Lidija Ljubicic et al., published by Sciendo. FAU - Ljubicic, Lidija AU - Ljubicic L AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Janzic, Urska AU - Janzic U AD - Medical Oncology Unit, University Clinic Golnik, Golnik, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. FAU - Unk, Mojca AU - Unk M AD - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. AD - Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. FAU - Terglav, Ana Sophie AU - Terglav AS AD - Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. FAU - Mohorcic, Katja AU - Mohorcic K AD - Medical Oncology Unit, University Clinic Golnik, Golnik, Slovenia. FAU - Seiwerth, Fran AU - Seiwerth F AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Bitar, Lela AU - Bitar L AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Badovinac, Sonja AU - Badovinac S AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Plestina, Sanja AU - Plestina S AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Rijeka, Rijeka, Croatia. FAU - Korsic, Marta AU - Korsic M AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Kukulj, Suzana AU - Kukulj S AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Samarzija, Miroslav AU - Samarzija M AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Jakopovic, Marko AU - Jakopovic M AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230904 PL - Poland TA - Radiol Oncol JT - Radiology and oncology JID - 9317213 RN - 15H5577CQD (Docetaxel) RN - G6HRD2P839 (nintedanib) SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/drug therapy MH - Docetaxel/therapeutic use MH - Retrospective Studies MH - *Lung Neoplasms/drug therapy MH - Lung PMC - PMC10476899 OTO - NOTNLM OT - advanced NSCLC OT - antiangiogenic therapy OT - docetaxel OT - nintedanib OT - real-world data EDAT- 2023/09/04 18:41 MHDA- 2023/09/06 06:42 PMCR- 2023/09/01 CRDT- 2023/09/04 14:13 PHST- 2023/05/15 00:00 [received] PHST- 2023/07/16 00:00 [accepted] PHST- 2023/09/06 06:42 [medline] PHST- 2023/09/04 18:41 [pubmed] PHST- 2023/09/04 14:13 [entrez] PHST- 2023/09/01 00:00 [pmc-release] AID - raon-2023-0040 [pii] AID - 10.2478/raon-2023-0040 [doi] PST - epublish SO - Radiol Oncol. 2023 Sep 4;57(3):397-404. doi: 10.2478/raon-2023-0040. eCollection 2023 Sep 1.